1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Techno Medica Co., Ltd.

Techno Medica Co., Ltd.

TTSE:6678
2,088.00
JPY
-12.00
(-0.57%)
15.59BMarket Cap
Nov 06Next Earn
Techno Medica Co., Ltd.
TSE:6678
(Tokyo Stock Exchange)

Recent

price

2,088.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
862.95
911.07
930.5
1,027.4
1,043.97
1,032.12
982.28
1,005.56
1,088.94
1,155.51
1,064.35
1,141.82
1,109.93
1,319.31
1,430.55
1,629.18
- -
Revenue per Share
106.57
122.65
141.98
154.69
163.14
136.78
53.21
152.04
128.13
117.84
135.78
150.85
136.35
172.95
145.08
155.28
- -
Basic EPS, GAAP
83.02
83.51
136.39
97.83
194.94
122.69
75.44
169.38
70.67
99.39
93.19
233.43
88.69
133.48
136.61
153.6
- -
Free Cash Flow per Basic Share
25.37
25.38
29.34
30.34
32.98
43
42.98
42.98
45.01
47.46
48.9
51.12
59.85
65.22
67.9
68.3
- -
Dividend per Share
938.24
1,035.56
1,148.21
1,272.55
1,321.75
1,403.18
1,413.38
1,519.6
1,603.12
1,668.69
1,755.98
1,858.62
1,933.86
1,998.92
2,076.86
2,161.65
- -
Book Value per Share
937.29
1,034.81
1,147.63
1,268.49
1,318.21
1,400.59
1,410.7
1,517.37
1,599
1,665.26
1,753.18
1,854.7
1,931.15
1,988.6
2,068.23
2,154.59
- -
Tangible Book Value per Share
9
9
9
9
9
9
9
9
9
8
8
8
8
8
7
7
7
Basic Weighted Avg Shares
7,559
7,981
8,151
9,000
9,145
9,032
8,457
8,654
9,332
9,811
9,040
9,699
9,368
10,284
9,906
11,237
- -
Sales/Revenue/Turnover
19.2
22.91
23.8
23.96
25.02
18.17
16.77
17.24
16.26
12.82
17.79
19.2
17.61
17.89
13.13
14.85
- -
Operating Margin (%)
44
39
41
55
90
75
72
71
71
94
121
121
108
113
100
92
- -
Depreciation Expense
934
1,074
1,244
1,355
1,429
1,197
458
1,309
1,098
1,000
1,153
1,281
1,151
1,348
1,005
1,071
- -
Net Income, GAAP
35.78
41.33
36.05
37.25
36.47
33.61
24.57
21.68
29.14
25.28
30.08
30.78
30.92
27.54
23.88
29.78
- -
Effective Tax Rate (%)
12.35
13.46
15.26
15.06
15.63
13.25
5.42
15.12
11.77
10.2
12.76
13.21
12.28
13.11
10.14
9.53
- -
Profit Margin (%)
6,966
7,834
8,773
9,696
10,266
10,843
11,010
11,602
12,243
12,285
13,086
13,843
14,497
11,722
12,403
12,613
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
8,219
9,071
10,058
11,148
11,578
12,081
12,169
13,018
13,742
14,149
14,960
15,650
16,387
13,819
14,389
14,410
- -
Total Equity
11.22
11.63
12.22
12.2
12.19
8.8
8.55
9.01
7.83
6.62
7.55
8.16
6.95
8.63
6.89
7.96
- -
Return on Invested Capital (%)
11.7
12.3
12.94
12.78
12.58
10.12
3.78
10.39
8.21
7.17
7.92
8.37
7.18
8.93
7.12
7.44
- -
Return on Capital (%)
11.87
12.43
13
12.78
12.58
10.12
3.78
10.39
8.21
7.17
7.92
8.37
7.18
8.93
7.12
7.44
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
13,699
15,593
13,110

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
14,356
15,696
- -
Cash, Cash Equivalents & STI
8,808
8,976
- -
Accounts Receivable, Net
2,039
3,437
- -
Inventories
3,051
2,282
- -
Total Current Liabilities
2,131
3,083
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.99%
-0.41%
0.15%
Free Cash Flow
18.98%
26.04%
11.99%
Net Income, GAAP
11.34%
-0.16%
6.61%
Sales/Revenue/Turnover
2.45%
4.68%
13.43%
Total Cash Common Dividend
2.43%
2.84%
0.19%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
9,906
2026
- -
- -
- -
- -
11,237
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
145.08
2026
- -
- -
- -
- -
155.28
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
67.9
2026
- -
- -
- -
- -
68.3
2027
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Techno Medica Co., Ltd. engages in the research, development, manufacture, sale, import, and export of clinical laboratory equipment, specializing in in-vitro diagnostic analyzers and related medical devices. The company's product portfolio includes automated tube selecting and labeling systems; RFID-based specimen management systems; blood and urine collection support devices; pre-analytical instruments; blood gas analyzers; electrolyte analyzers; erythrocyte sedimentation rate measuring machines; and consumables such as blood collecting tubes, labels, sensor cards, and calibration packs. Techno Medica integrates its devices with information technology support systems to enhance laboratory workflow accuracy and efficiency. Since its founding in 1987 and headquartered in Japan, the company operates primarily in the Japanese market with exports and business presence extending to Korea, China, ASEAN countries, and Europe. Recently, Techno Medica has focused on innovations that improve patient care and laboratory efficiency, notably advancing automation technology with products such as the BC ROBO-8001 RFID system and the TRIPS process control system. These RFID-enabled solutions streamline specimen handling, reduce pre-analytical errors, and are tailored for hospitals of varying sizes. Additionally, the company introduced a blood collection reservation system that gained attention during the COVID-19 pandemic for enhancing outpatient service efficiency. In the last 1-2 years, Techno Medica has maintained stable financial positioning with slight fluctuations in revenue and profit, while continuing to strengthen its product offerings and expand market reach through technological integration and process automation. Techno Medica serves clinical laboratories, hospitals, and medical institutions with its comprehensive range of medical diagnostic instruments and consumables, underlining its strategic focus on innovation and system integration to support the evolving needs of healthcare providers.